About us
The Hereditary Cancer Group at IDIBELL is involved in several global projects, involving regional, national and international initiatives of genomic-based precision medicine in cancer.
- Hereditary Cancer Research Group – AGAUR
- IMPaCT_GENóMICA
- IMPaCT_VUSCan
- SpadaHC
Group members
Management Support
Patricia Prada
Project Manager
Guillem Torcal Garcia
Project Manager
Patricia Prada
Project Manager
I graduated in Genetics at the Autonomous University of Barcelona (UAB) in 2014, then I completed a master’s degree in Biological Anthropology, Human Diversity and Biomedical Applications at the University of Barcelona together with the Autonomous University of Barcelona in 2015. At this time, I performed my master’s thesis focused on the genetic study of Lewy body diseases, supervised by Dr. Katrin Beyer and Dr. Cristina Santos at the Hospital Germans Trias i Pujol. Following with neuroscience research, I pursued my PhD (2020) in the mitochondrial neuropathology lab led by Dr. Albert Quintana and Dr. Elisenda Sanz. I was keen on deciphering the neuronal type specific contribution at transcriptomic (nuclear and mitochondrial) level in Leigh syndrome mitochondrial disorder. Supporting this research, I did a short stay in Dr. Rita Horvath’s lab in Cambridge University (UK). Additionally, I collaborated with industry stakeholders in pre-clinical pharmacological studies for mitochondrial pathologies, coordinated a master’s thesis and collaborated in university teaching at the UAB. Then, I decided to direct my career path towards a translational research and clinical support. In 2021 I joined Hereditary Cancer Group at the IDIBELL as Project Manager while coursing a clinical genetics postgraduate course.
Guillem Torcal Garcia
Project Manager
Guillem obtained his B.Sc. in Molecular Biology by the University of Barcelona (UB) in 2013, performing research internships in both the Developmental Genetics and Biology group and the Unit of Botany of the University of Barcelona (UB) as well as the Chromatin Dynamics group at the University of Copenhagen (KU). He performed a research internship in the group of Dr. Kristian Helin at the Biotech Research & Innovation Center in Copenhagen, Denmark (2013-2014), and continued his studies obtaining an M.Sc. in Human Biology by the University of Copenhagen (KU) (2016). He performed his master thesis at the laboratory of Dr. Kim Jensen at the Biotech Research & Innovation Center (currently reNEW) in Copenhagen, Denmark (2016). He pursued his Ph.D. in Biomedicine at the Hematopoietic Stem Cells, Transdifferentiation and Reprogramming group led by Dr. Thomas Graf at the Centre for Genomic Regulation (CRG) in Barcelona. He defended his Ph.D. thesis in 2022, focusing on the role of post-translational modifications of transcription factors in cell fate decisions. He joined the Hereditary Cancer group at IDIBELL as a Project Manager to aid in the steering of global translational and clinical projects.
Postdoctoral researchers
Mireia Ramos-Muntada
Postdoctoral investigator
Mireia Ramos-Muntada
Postdoctoral investigator
I am a postdoctoral researcher graduated in Genetics from the Universitat Autònoma de Barcelona (UAB) in 2015. I continued my university education with the Postgraduate course in Medical Genetics by the Universitat de València (2016-2017) and the Master’s Degree in Cytogenetics and Reproductive Biology by UAB (2017-2018). I did my Master Thesis in the Genetics of Male Fertility Group, characterizing genetic risk in carriers of chromosome heteromorphisms. After that, I started my Phd (2018-2021) at the same group, under the joint supervision of Dra. Francesca Vidal and Dr. Joan Blanco. There, I studied 22q11.2 deletion syndrome as a model study for the integral analysis of genetic factors that predispose genomic disorders. At this time, I entered at the Next Generation Sequencing (NGS) analysis world. Meanwhile, I collaborated in the study of clonal heterogeneity and evaluation in relapse high-hyperdiploid B-cell acute lymphoblastic leukaemia, with Dr. Oscar Molina and Dr. Pablo Menéndez from Josep Carreras Leukaemia Research Institute. During these years, I published two books and several divulgation articles to bring genetics to the general population. In 2021 I joined to Hereditary Cancer Group at IDIBELL as a NGS data analyst.
I graduated in Genetics at the Autonomous University of Barcelona (UAB) in 2014, then I completed a master’s degree in Biological Anthropology, Human Diversity and Biomedical Applications at the University of Barcelona together with the Autonomous University of Barcelona in 2015. At this time, I performed my master’s thesis focused on the genetic study of Lewy body diseases, supervised by Dr. Katrin Beyer and Dr. Cristina Santos at the Hospital Germans Trias i Pujol. Following with neuroscience research, I pursued my PhD (2020) in the mitochondrial neuropathology lab led by Dr. Albert Quintana and Dr. Elisenda Sanz. I was keen on deciphering the neuronal type specific contribution at transcriptomic (nuclear and mitochondrial) level in Leigh syndrome mitochondrial disorder. Supporting this research, I did a short stay in Dr. Rita Horvath’s lab in Cambridge University (UK). Additionally, I collaborated with industry stakeholders in pre-clinical pharmacological studies for mitochondrial pathologies, coordinated a master’s thesis and collaborated in university teaching at the UAB. Then, I decided to direct my career path towards a translational research and clinical support. In 2021 I joined Hereditary Cancer Group at the IDIBELL as Project Manager while coursing a clinical genetics postgraduate course.
Guillem obtained his B.Sc. in Molecular Biology by the University of Barcelona (UB) in 2013, performing research internships in both the Developmental Genetics and Biology group and the Unit of Botany of the University of Barcelona (UB) as well as the Chromatin Dynamics group at the University of Copenhagen (KU). He performed a research internship in the group of Dr. Kristian Helin at the Biotech Research & Innovation Center in Copenhagen, Denmark (2013-2014), and continued his studies obtaining an M.Sc. in Human Biology by the University of Copenhagen (KU) (2016). He performed his master thesis at the laboratory of Dr. Kim Jensen at the Biotech Research & Innovation Center (currently reNEW) in Copenhagen, Denmark (2016). He pursued his Ph.D. in Biomedicine at the Hematopoietic Stem Cells, Transdifferentiation and Reprogramming group led by Dr. Thomas Graf at the Centre for Genomic Regulation (CRG) in Barcelona. He defended his Ph.D. thesis in 2022, focusing on the role of post-translational modifications of transcription factors in cell fate decisions. He joined the Hereditary Cancer group at IDIBELL as a Project Manager to aid in the steering of global translational and clinical projects.
I am a postdoctoral researcher graduated in Genetics from the Universitat Autònoma de Barcelona (UAB) in 2015. I continued my university education with the Postgraduate course in Medical Genetics by the Universitat de València (2016-2017) and the Master’s Degree in Cytogenetics and Reproductive Biology by UAB (2017-2018). I did my Master Thesis in the Genetics of Male Fertility Group, characterizing genetic risk in carriers of chromosome heteromorphisms. After that, I started my Phd (2018-2021) at the same group, under the joint supervision of Dra. Francesca Vidal and Dr. Joan Blanco. There, I studied 22q11.2 deletion syndrome as a model study for the integral analysis of genetic factors that predispose genomic disorders. At this time, I entered at the Next Generation Sequencing (NGS) analysis world. Meanwhile, I collaborated in the study of clonal heterogeneity and evaluation in relapse high-hyperdiploid B-cell acute lymphoblastic leukaemia, with Dr. Oscar Molina and Dr. Pablo Menéndez from Josep Carreras Leukaemia Research Institute. During these years, I published two books and several divulgation articles to bring genetics to the general population. In 2021 I joined to Hereditary Cancer Group at IDIBELL as a NGS data analyst.
Projects
Hereditary Cancer Research Group – AGAUR
07/03/2023 — 15/03/2045
We are a multidisciplinary-multicentric research group (ICO-IDIBELL-IDIBGI-Vall Hebron-VHIO) that have worked for more than 20 years offering genetic counseling, molecular diagnosis and hereditary cancer research accomplishment. Our main goal is to know more precisely the basis of hereditary cancer in order to be able to personalize the estimation of the risk of patients and relatives… Read more »
IMPaCT-VUScan: Development and implementation of a functional genomics platform for undiagnosed hereditary cancer
01/01/2023 — 31/12/2025
IMPaCT-VUScan is an initiative that aims to identify variants of unknown significance (VUS) in suspected hereditary cancers. The IMPaCT-Genómica initiative has already developed a basic platform and workflows to evaluate unsolved cases with suspected genetic diseases, including hereditary cancer cases. However, it is expected that multiple VUS will be identified in most, if not all,… Read more »
SpadaHC: Spanish DataBase for Hereditary Cancer
01/01/2022 — 01/05/2123
Database for sharing genetic variants in hereditary cancer genes and their interpretation from expert panels and Spanish genetic diagnostics laboratories. The database also provides population frequencies of variants in Spanish individuals based on their clinical suspicion of cancer predisposition. The ultimate purpose of SpadaHC is to offer a useful resource for the research community and… Read more »
IMPaCT Genómica: Implementation of Precision Medicine in the Spanish National Health System.
01/05/2020 — 31/12/2023
The Cancer Working Package (WP4) of the IMPaCT Genómica program aims to improve the diagnosis, prevention, and treatment of suspected hereditary cancers and cancers of unknown origin that have not been resolved with the current tools of the healthcare system. The WP4 team, led by Dr. Gabriel Capellà (IDIBELL) collaborates with over 80 healthcare professionals… Read more »
Contact
If you have any doubts or concerns about this research team, contact us by filling this form